Intriguingly, the antidepressant fluoxetine, a selective serotonin reuptake inhibitor and the only drug which has been shown to improve poststroke motor recovery in a randomized controlled neurorehabilitation trial in stroke patients [16], has recently been shown to inhibit ASM activity in the rodent healthy brain [17]. Here, SMPD1 is linked to stroke disorder.